Inbox - part-time employment (we believe that the sender has used the law firm www.relmanlaw.com as a front & are investigating)

Speech of welcome


I work as a manager at a large company. Our company takes an active part in the life of its subsidiaries, for example:
- companies setting-up
– companies winding-up
– opening accounts in Europe
– etc.

We need employees in Europe:
- salary 2.500 euro + bonus
- 1-2 working hours per day
- flexible work time


If you are ready to work as a regional manager in Europe send us the below information on email:

h r @ e u r j o b s . o r g [please delete spaces before sending]

Do not complete as we believe this is a Phishing attempt  Scammers use a know respectable name in the industry - in this casetheir domain leaving out the eurojobs.com  "O"
Name:
Surname:
Country:
E-mail:
Mobile phone-number:
Attention! We are looking for the people who have a right to work in Europe!

Please, write your name and Telephone Number so that our manager could contact you and conduct an interview.  

Information for the Police / Interpol
Return-Path: <sicknessesru@relmanlaw.com>
Received: from dsldevice.lan (adsl190-28-77-244.epm.net.co [190.28.77.244])
 by mailer.ran.es (8.14.2/8.13.8) with ESMTP id o6THQErY024890
 for ; Thu, 29 Jul 2010 19:26:32 +0200
Received: from 190.28.77.244 by relmanlaw.com.s5b1.psmtp.com; Thu, 29 Jul 2010 12:26:12 -0500
Message-ID: <000d01cb2f43$23f5b290$6400a8c0@sicknessesru>
From: "Pryor0BRNIS" <Pryor0BRNIS@we-help-u.biz>
To: <?>Subject: part-time employment
Date: Thu, 29 Jul 2010 12:26:12 -0500
MIME-Version: 1.0
Content-Type: multipart/alternative;
 boundary="----=_NextPart_000_0007_01CB2F43.23F5B290"
X-Priority: 3
X-MSMail-Priority: Normal
X-Mailer: Microsoft Outlook Express 6.00.2900.2180
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2180
X-UIDL: 0SM"!L9N!!^,$"!%PY!!
Old-X-EsetId: E74D982990713469F84B987D9E2570
Old-X-EsetId: E74D982990713469F84B987D9E2570
X-EsetScannerBuild: 7563
X-EsetId: E74D982990713469F84B987D9E2572

We have contacted the law firm www.relmanlaw.com  to ascertain whether or not they sent this letter. They have used the respectable law firms name for the Return Path sicknessru@relmanlaw.com - the sicknessru not existing @relmanlaw.com being genuine
Of course they know that the potential victim will not go looking for this information in "Archives" having placed the mouse over the Subject heading and then Properties

 Relman, Dane & Colfax PLLC

1225 19th St. NW, Suite 600
Washington, DC 20036
USA

(202) 728-1888

(202) 728-0848

info@relmanlaw.com

Inbox - FROM THE DESK OF THE MR DAVID WILLIAMS - 419 Nigerian Scam email

FROM THE DESK OF THE MR DAVID WILLIAMS     
                        [OFFICE OF MR DAVID WILLIAMS]
                       E-Mail:ibankplc1@gmail.com
                      PHONE +234-7080155452
               

Well known to all The Intercontinental Bank Plc is a commercial Banks here in Nigeria. Really these men were unexpected by me because their visit was impromptu. I had to ask them why they came to see me in person and they said that they were here to collect the Inheritance Bill Sum of (US$30 Million) which rightfully belongs to you, on your behalf. At this development I asked them who authorized them to come down to Nigeria for the Collection of this Payment and they told me that you asked them to come and collect this Funds on your Behalf.

1. LETTER OF ADMINISTRATION.

2. HIGH COURT INJUCTION.

3. ORDER TO RELEASE.

Actually, these Documents which they tendered to this Noble Bank are a clear Proof that you sent them to Collect this Funds for you. Finally, I told them to come back on tuesday morning and they promised to come back. As the Director of this Noble Bank, I was supposed to Release this Funds to them but I refused to do so because I wanted to hear from you first.

Due to the Nature of my job,I will not want to make any mistake in Releasing this Funds to anyone except you whom is the Recognized Beneficiary to this Funds. Kindly clarify us on this issue before we make this Payment to these foreigners whom came on your behalf.


Also I told them to come with their lawyer who will sign the final release bond for them in order for the fund to be released to them in cash.

I also took their photograph in order for you to know I am not kidding or joking here, this is a serious matter and if you are still willing to receive your fund then you should act fast in raising the fee of $350 needed for your fund to be released to you.

Call me on my direct line +234-7080155452

I awaiting to hear from you

Yours Sincerely,


Mr.David Williams
Director of Intercontinental Bank Plc
E-mail:ibankplc1@gmail.com

.

Information for the Police / Interpol

Subject:  FROM THE DESK OF THE MR DAVID WILLIAMS     
Date: Thu, 29 Jul 2010 08:46:39 -0700
MIME-Version: 1.0
Content-Type: text/plain;
 charset="Windows-1251"
Content-Transfer-Encoding: 7bit
X-Priority: 3
X-MSMail-Priority: Normal
X-Mailer: Microsoft Outlook Express 6.00.2600.0000
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2600.0000
Bcc:
Message-ID: <PPGT1MHffNPL83mxMAK000008c1@ppgt1.PPGT.KZ>
X-OriginalArrivalTime: 29 Jul 2010 15:46:41.0412 (UTC) FILETIME=[3D0B6440:01CB2F35]
X-UIDL: CNX"!Y:k!!^8U"!AjC!!
Old-X-EsetId: E74D982990713469F84B987D9E2570
X-EsetId: E74D982990713469F84B987D9E2570
X-EsetScannerBuild: 7561

Comet has some sizzling codes just in time for the weekend. Panasonic ZX3/ TZ8/TZ10 - Camcaroders Panasonic SD60 & Sony CX11

Capture every moment this Summer with this selection of digital cameras and camcorders, and enjoy an extra 5% off!

5% off products over £200 (EXCLUDING Apple iPad)
5OFF
Expires Tue 3 Aug 10
Product selection
Panasonic ZX3 £207.00 PLUS 5% CODE = £196.65



Panasonic TZ8 £204.00 PLUS 5% CODE = £193.80



Panasonic TZ10 £252.63 PLUS 5% CODE =£ 204.02



Panasonic SD60 £340.00 PLUS 5% CODE = £323
 
Sony CX11 £336.55 PLUS 5% CODE = £319.73



Code: 30JVC32
Expiry Date: 31 July 2010
JVC LT-32DG20J LCD TV Was £ 549.99 Now £349.99 Save a further £30 with voucher code 30JVC32 making it £319.99



Goldbug100 - AIDA Pharmaceuticals, Inc. (AIDA.PK)

31 Dingjiang Road

Jianggan District
Hangzhou   ZHJ   310016
P: +86571.85802712

Company Web Links

• Home Page
• News Releases
• Financial Information
• Corporate History/Profile
• Products/Services

IDA Pharmaceuticals, Inc., incorporated in December 18, 2002, and located in Hangzhou, the People’s Republic of China, operates through its subsidiaries, which include Earjoy Group Limited (Earjoy), Hangzhou Aida Pharmaceutical Co., Ltd (Hangzhou Aida), Hangzhou Boda Medical Research and Development Co., Ltd. (Boda), Hainan Aike Pharmaceutical Co., Ltd. (Aike), Changzhou Fangyuan Pharmaceutical Co., Ltd. (Fangyuan) and Shanghai Qiaer Bio-technology Co., Ltd (Qiaer). Earjoy is an investment holding company. Hangzhou Aida is a pharmaceutical company engaged in the development, manufacture, marketing, licensing, and distribution of pharmaceutical products primarily in mainland China. Hangzhou Aida has a total of nine production lines for the manufacture of antibiotics, cardiovascular and anti-tumor drugs in various forms, including injectable powder, injectable liquid, capsules, tablets and ointments. Hangzhou Aida’s primary product is the injectable powder form of Etimicin Sulfate.

Boda is a wholly owned subsidiary of Hangzhou Aida and engages itself in the research and development of new drugs. Aike specializes in the production of transfusion type of Etimicin AiYi. Fangyuan is a 66%-owned subsidiary of Hangzhou Aida. Fangyuan is a supplier of raw material for Etimicin and is also a producer of the liquid type of Etimicin ChuangCheng. The key product of Qiaer is Apoptotic Factor (rh-Apo2l), a potential biopharmaceutical therapy with genetic engineering techniques used for cancers.

On March 26, 2008, Hangzhou Aida signed a purchase agreement with Jin’ou Medicine Co., Ltd to acquire a 43% equity interest in Jiangsu Institute of Microbiology Co., Ltd. On March 26, 2008, Fangyuan signed a purchase agreement with Jiangyin Hi-tech Group to acquire 55% interest in Jiangsu Institute of Microbiology Co., Ltd. 

Etimicin Sulfate is an amino glycoside family of antibiotics. It is suitable for the treatment of various inflammations, including respiratory infection, such as acute bronchitis, acute onset of chronic bronchitis and pulmonary infections; kidney and urinogenital infection, such as acute pyelonephritis or acute onset of chronic cystitis; soft skin tissue infection, and trauma and operations (before and after) preventive uses. 

The products being developed by AIDA Pharmaceuticals include rh-Apo2l, Vasostatin –Apo2L, Prodigiosin, Anti-CD86 Monoclonal Antibody and Anti-CTLA-4 Monoclonal Antibody. Rh-Apo2l is being evaluated in a Phase II trial which started in February 2007. Vasostatin –Apo2L is a recombinant fusion protein that is being tested as a potential cancer drug. It integrates the function of extracted fragment of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of rh-Apo2l which induces the apoptosis of cancer cells. Prodigiosin, a naturally occurring red pigment, is in pre-clinical trials for the treatment of pancreatic cancer. 

Certain immunity diseases activate T-cells (a type of white blood cell), causing them to unnecessarily attack healthy tissue. Anti-CD86 Monoclonal Antibody inhibits T-cells from harming healthy tissue. In the case of certain cancers, tumors over-express self-proteins, essentially hiding the tumor from the immune system. The Company is in the development stages of an Anti-CTLA-4 Monoclonal Antibody, which may relieve the inhibition of T-cells allowing them to identify the over-expressed proteins and in turn naturally attacking cancer cells without harming healthy tissues.

AIDA Pharmaceuticals's main production facilities are located in Hangzhou in the Zhejiang Province, in Changzhou in the Jiangsu Province and in Haikou in the Hainan Province. The raw materials and supplies for manufacturing at the plants are sourced from suppliers in China. The supplier for Etimicin Sulfate base aside from Fangyuan is Shanhe Pharmaceuticals Co., Ltd. in Wuxi, Jiangsu Province.

In the Goldbug 100 portolio - the Fund Manager feels that a HKSE listing would be better for this company than the current Pink Sheet one, but of course the listing costs may prohibit this. Price paid $1.15 at the peak of the bull market in 2008. The fund does not like the reporting of Pink Sheet shares. AIM on the London Stock Exchange shows potential investors far more details.
.

Important information for the investor - Price earning ratio / assets per share and of course future dividend policy etc. The fund in view of the lack of reporting of Pink Sheet shares really is reluctant to "average out" on it´s holdings in PS companies which are more suitable to "day traders" and are the fodder of "Pump and dump" internet web sites who paint a rosy picture of their client´s prospects